Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
Top Cited Papers
- 1 October 2001
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 358 (9288), 1119-1123
- https://doi.org/10.1016/s0140-6736(01)06250-x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary HypertensionCirculation, 2000
- Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin AnalogueNew England Journal of Medicine, 2000
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- EndothelinB receptor‐mediated contraction in human pulmonary resistance arteriesBritish Journal of Pharmacology, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Endothelin and Collagen Vascular Disease: A Review with Special Reference to Raynaud's Phenomenon and Systemic Sclerosis.Internal Medicine, 1994
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993
- Endothelin-1-Like Immunoreactivitγ in Postobstructive Pulmonary VasculopathyJournal of Vascular Research, 1993
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992
- Pulmonary hypertension in the crest syndrome variant of systemic sclerosisArthritis & Rheumatism, 1986